Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: V03AB35

Bridion(sugammadex)

Neuromuscular Blockade

Marketing Authorisation Holder: Merck Sharp & Dohme B.V.

EMA Authorisation: 25/07/2008

INN: sugammadex

Indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bridion — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.